Antipsychotic switching in bipolar disorders: a systematic review
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
With the increasingly widespread use of antipsychotics in bipolar disorder (BD), switching among these agents and between antipsychotics and mood stabilizers has become more common, in particular, since the introduction of the novel atypical antipsychotics with mood stabilizer properties. This systematic review aims to provide a comprehensive update of the current literature in BD about the switching of antipsychotics, among them and between them and mood stabilizers, in acute and maintenance treatment. We conducted a comprehensive, computerized literature search using terms related to antipsychotic switching in BD in the PubMed/Medline, PsycINFO, CINAHL database; the Cochrane Library and; the Clinicaltrials.gov web up to January 9th, 2013 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The search returned 4160 articles. After excluding duplications, reviews, case reports and studies that did not fulfil the selection criteria, 8 studies were included. Not only have few articles on antipsychotic switching been published but also recruitment in most studies included mixed samples of patients. In general, antipsychotic switching, regardless of the route of drug administration, was well tolerated and no interference was shown in antipsychotic effectiveness during the interchange of drugs. Metabolic improvement was perceived when the switch involved antipsychotics with a low metabolic risk profile. The evidence-base for antipsychotic switching in BD is scant, and little controlled data is available. Switch from quetiapine to lithium and from risperidone to olanzapine has proven successful. Switching to antipsychotics with low metabolic risk had some positive impact on several safety measures. In stabilized patients, the plateau cross-taper switch may be preferred.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145 · cited 2×
“…the side effects that may occur in long-term treatment, the metabolic and cardiovascular profiles of antipsychotics are of concern among patients and physicians, in particular, those drugs with a high histaminergic affinity such as clozapine and olanzapine (Buckley, 2007; De Hert et al., 2012).”
Weisler, R. H., Nolen, W. A., Neijber, A., Hellqvist, Å., Paulsson, B., & Trial 144 Study Investigators (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m06878 · Cited by 169
Vieta, E., Montgomery, S., Sulaiman, A. H., Cordoba, R., Huberlant, B., Martinez, L., & Schreiner, A. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.03.004 · Cited by 130 · cited 5×
“The randomized controlled trials by Weisler et al. (2011) and Vieta et al. (2012) have an enriched design.”
InfluentialSelf-citationCruz, N., Sanchez-Moreno, J., Torres, F., Goikolea, J. M., Valentí, M., & Vieta, E. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990344 · Cited by 121 · cited 2×
“, 2013; Vieta and Valentí, 2013a), but antipsychotics are also a well-grounded treatment for acute depression and the prevention of relapses (Cruz et al., 2010; Frye et al., 2011; Nivoli et al., 2011a; Vieta et al., 2011; Grunze et al., 2013; Vieta and Valentí, 2013b).”
Self-citationBrown, E. S., Jeffress, J., Liggin, J. D. M., Garza, M., & Beard, L. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0613 · Cited by 118 · cited 6×
“(Brown et al., 2005) 19 BD-I/II patients on current substance abuse (out of 20) Retrospective open-label study with cross-taper switch from A to aripiprazole 12 Efficacy: YMRS, HDRS, BPRS, substance craving VAS, dollars spent, substance use Safety: BARS, SAS, AIMS Significant clinical improvement without changes in to…”
Influential
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Self-citationGrande, I., Berk, M., Birmaher, B., & Vieta, E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00241-x · Cited by 1,710
Self-citationYildiz, A., Nikodem, M., Vieta, E., Correll, C. U., & Baldessarini, R. J. (2015) · Psychological Medicine · doi:10.1017/s0033291714001305 · Cited by 128
“However, olanzapine risks weight gain and metabolic syndrome in the longer term (Centorrino et al. 2012; Grande et al. 2014; Mizuno et al. 2014).”
BackgroundSelf-citationMontejo, Á. L., Arango, C., Bernardo, M., Carrasco, J. L., Crespo-Facorro, B., Cruz, J. J., Del Pino-Montes, J., García-Escudero, M. A., García-Rizo, C., González-Pinto, A., et al. (2017) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.02.003 · Cited by 75
Self-citation
Metadata
- Authors
- Grande, I., Bernardo, M., Bobes, J., Saiz-Ruiz, J., Álamo, C., & Vieta, E.
- Venue
- The International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-10-21
- Volume
- 17
- Issue
- 03
- Pages
- 497-507
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2150020926
- Cited by
- 30
- References
- 5
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antipsychotic switching in bipolar disorders: a systematic review. https://app.cochat.ai/papers/10.1017/s1461145713001168
- The paper
- Grande, I., Bernardo, M., Bobes, J., Saiz-Ruiz, J., Álamo, C., & Vieta, E. (2014). Antipsychotic switching in bipolar disorders: a systematic review. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145713001168
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.